
Transtema - Set for Exciting 2023

Redeye retains its positive view of Transtema and foresees a strong 2023 fueled by organic and acquired sales growth combined with a slight margin improvement. Recent acquisitions reduce the group's customer concentration and strengthen its offerings in several growth areas.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Transtema - Set for Exciting 2023](#)